NECA have been involved in the development of Guidelines for “ Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs” which is now published and has been endorsed by the Commonwealth Neuroendocrine Tumour Collaboration and the North American Neuroendocrine Tumour Society.
After an extensive literature review, multidisciplinary in person workshop and Delphi methos – the quality of evidence and strength of recommendations were determined using the Grading of Recommendations, Assessment, Development and Evaluations framework. The study results suggest that select factors have sufficient evidence to inform care in GEP-NENs, but the evidence for most biomarkers is weak.
Read the Published article here along with the supplement
